Total Payments
$296,749
2024 Payments
$7,764
Companies
10
Transactions
225
Medicare Patients
18,157
Medicare Billing
$552,403
Payment Breakdown by Category
Consulting$197,935 (66.7%)
Research$98,605 (33.2%)
Food & Beverage$209.19 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $197,935 | 204 | 66.7% |
| Unspecified | $98,605 | 13 | 33.2% |
| Food and Beverage | $209.19 | 8 | 0.1% |
Payments by Type
General
$198,144
212 transactions
Research
$98,605
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $197,935 | 204 | $0 (2021) |
| Eli Lilly and Company | $62,115 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $36,490 | 4 | $0 (2024) |
| NOVADAQ TECHNOLOGIES INC. | $109.82 | 2 | $0 (2017) |
| Covidien LP | $22.10 | 1 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $17.99 | 1 | $0 (2017) |
| Medtronic, Inc. | $17.43 | 1 | $0 (2021) |
| Cook Incorporated | $16.31 | 1 | $0 (2017) |
| Philips North America LLC | $14.15 | 1 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $11.39 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,764 | 3 | E.R. Squibb & Sons, L.L.C. ($4,955) |
| 2023 | $29,225 | 2 | E.R. Squibb & Sons, L.L.C. ($19,750) |
| 2022 | $17,890 | 5 | E.R. Squibb & Sons, L.L.C. ($10,155) |
| 2021 | $115,482 | 108 | Merck Sharp & Dohme Corporation ($113,835) |
| 2020 | $80,430 | 84 | Merck Sharp & Dohme Corporation ($80,200) |
| 2019 | $3,900 | 15 | Merck Sharp & Dohme Corporation ($3,900) |
| 2018 | $1,022 | 2 | Eli Lilly and Company ($1,000) |
| 2017 | $41,036 | 6 | Eli Lilly and Company ($40,880) |
All Payment Transactions
225 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Philips North America LLC | (8317) ProxiDiagnost N90 High Performance (Device) | Food and Beverage | Cash or cash equivalent | $14.15 | General |
| Category: Medical Device | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $4,955.00 | Research |
| Study: Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo • Category: Oncology | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,795.00 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $19,750.00 | Research |
| Study: Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo • Category: Oncology | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,475.00 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 10/06/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,900.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 10/06/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADUCANUMAB-AVWA IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 06/08/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 05/04/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,435.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 02/03/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $10,155.00 | Research |
| Study: Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo • Category: Oncology | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $835.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $440.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $395.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $80.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $80.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $635.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $560.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Consulting Fee | Cash or cash equivalent | $560.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT RAMUCIRUMAB AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA-RAINFALL | Eli Lilly and Company | $41,880 | 2 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono - A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo fo | E.R. Squibb & Sons, L.L.C. | $34,860 | 3 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $12,270 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $3,665 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,900 | 1 |
| Phase III Peri-Adjuvant NSCLC Nivo Mono | E.R. Squibb & Sons, L.L.C. | $1,630 | 1 |
| A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADUCANUMAB-AVWA IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,300 | 1 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $1,100 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 71 | 5,024 | 5,386 | $775,769 | $139,204 |
| 2022 | 61 | 4,841 | 5,123 | $719,552 | $148,425 |
| 2021 | 64 | 4,284 | 4,588 | $663,503 | $137,699 |
| 2020 | 63 | 4,008 | 4,441 | $688,862 | $127,074 |
Total Patients
18,157
Total Services
19,538
Medicare Billing
$552,403
Procedure Codes
268
All Medicare Procedures & Services
268 procedure records from CMS Medicare Utilization — Page 3 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 73630 | X-ray of foot, minimum of 3 views | Facility | 2023 | 61 | 74 | $2,812 | $445.85 | 15.9% |
| 74455 | Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | Facility | 2023 | 33 | 36 | $3,384 | $444.50 | 13.1% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Facility | 2023 | 20 | 20 | $1,905 | $429.94 | 22.6% |
| 73523 | X-ray of both hips, minimum of 5 views | Facility | 2023 | 35 | 35 | $1,820 | $388.03 | 21.3% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Facility | 2023 | 41 | 41 | $3,669 | $359.29 | 9.8% |
| 73130 | X-ray of hand, minimum of 3 views | Facility | 2023 | 34 | 49 | $1,752 | $305.89 | 17.5% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Facility | 2023 | 42 | 42 | $1,974 | $301.49 | 15.3% |
| 76604 | Ultrasound scan of chest | Facility | 2023 | 14 | 15 | $1,680 | $261.10 | 15.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 26 | 26 | $832.00 | $251.68 | 30.3% |
| 73110 | X-ray of wrist, minimum of 3 views | Facility | 2023 | 33 | 40 | $1,440 | $230.63 | 16.0% |
| 73610 | X-ray of ankle, minimum of 3 views | Facility | 2023 | 30 | 32 | $1,500 | $209.94 | 14.0% |
| 74022 | X-ray series of abdomen with single x-ray of chest | Facility | 2023 | 14 | 16 | $2,320 | $204.70 | 8.8% |
| 74430 | Review by radiologist of urinary bladder image | Facility | 2023 | 13 | 15 | $2,085 | $186.90 | 9.0% |
| 76098 | X-ray of surgical specimen | Facility | 2023 | 14 | 14 | $784.00 | $174.58 | 22.3% |
| 73590 | X-ray of lower leg, 2 views | Facility | 2023 | 22 | 25 | $925.00 | $140.47 | 15.2% |
| 73552 | X-ray of thigh bone, minimum 2 views | Facility | 2023 | 15 | 18 | $558.00 | $123.19 | 22.1% |
| 73060 | X-ray of upper arm, minimum of 2 views | Facility | 2023 | 12 | 19 | $660.00 | $119.52 | 18.1% |
| 73562 | X-ray of knee, 3 views | Facility | 2023 | 15 | 18 | $1,170 | $112.71 | 9.6% |
| 72050 | X-ray of upper spine, 4-5 views | Facility | 2023 | 14 | 14 | $924.00 | $108.47 | 11.7% |
| 73560 | X-ray of knee, 1-2 views | Facility | 2023 | 13 | 16 | $640.00 | $100.18 | 15.7% |
| 73080 | X-ray of elbow, minimum of 3 views | Facility | 2023 | 16 | 17 | $612.00 | $97.43 | 15.9% |
| 74021 | X-ray of abdomen, minimum of 3 views | Facility | 2023 | 11 | 11 | $627.00 | $94.71 | 15.1% |
| 73620 | X-ray of foot, 2 views | Facility | 2023 | 13 | 16 | $608.00 | $91.35 | 15.0% |
| 72070 | X-ray of middle spine, 2 views | Facility | 2023 | 11 | 11 | $891.00 | $80.70 | 9.1% |
| 77067 | Screening mammography | Facility | 2022 | 682 | 682 | $57,970 | $26,429 | 45.6% |
About Dr. David Udis, M.D
Dr. David Udis, M.D is a Diagnostic Radiology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861486409.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Udis, M.D has received a total of $296,749 in payments from pharmaceutical and medical device companies, with $7,764 received in 2024. These payments were reported across 225 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($197,935).
As a Medicare-enrolled provider, Udis has provided services to 18,157 Medicare beneficiaries, totaling 19,538 services with total Medicare billing of $552,403. Data is available for 4 years (2020–2023), covering 268 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Diagnostic Radiology
- Location Philadelphia, PA
- Active Since 09/09/2005
- Last Updated 01/08/2025
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1861486409
Products in Payments
- LENVIMA (Drug) $142,700
- KEYTRUDA (Biological) $55,235
- CYRAMZA (Drug) $41,880
- OPDIVO (Biological) $36,490
- SPY Technology (Device) $109.82
- Gadavist (Drug) $17.99
- Chameleon (Device) $17.43
- Cook Medical Drainage (Device) $16.31
- (8317) ProxiDiagnost N90 High Performance (Device) $14.15
- ANGIOJET ZELANTEDVT THROMBECTOMY CATHETER (Device) $11.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Philadelphia
Jill Langer, Md, MD
Diagnostic Radiology — Payments: $2.5M
Diagnostic Radiology $2.5M
Joan Prowda, Md, MD
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Lisa Jones, Md, MD
Diagnostic Radiology — Payments: $1.3M
Diagnostic Radiology $1.3M
Evan Siegelman, Md, MD
Diagnostic Radiology — Payments: $1.2M
Diagnostic Radiology $1.2M
Parvati Ramchandani, Md, MD
Diagnostic Radiology — Payments: $971,832
Diagnostic Radiology $971,832
Dr. Steven Finden, M.d, M.D
Diagnostic Radiology — Payments: $664,346
Diagnostic Radiology $664,346